Concepedia

Author

Shuichi Hironaka

National Cancer Center Hospital EastORCID

Also Known As

Hironaka Shuichi, S Hironaka, S. Hironaka, Shu-ichi Hironaka, Shuichi HIRONAKA, Shuichi Hironaka, Shu‐ichi Hironaka

246

Publications

10.4K

Citations

42

H-Index

48

Concepts

All Affiliations

National Cancer Center Hospital EastChiba Cancer CenterShizuoka Cancer CenterAichi Cancer CenterSaitama Cancer Center
SH

About

Shuichi Hironaka is an author at National Cancer Center Hospital East specializing in oncology, medicine, and radiation oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

29

54

7.6K

2

Gastroenterology

17

23

5.2K

3

Health Sciences

15

17

883

4

Cell Biology

1

1

99

5

Head And Neck Surgery

1

1

13

Shuichi Hironaka

×

89

Publications

10K

Citations

41

H-Index

YearCitations

Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial

H. Wilke, Kei Muro, Eric Van Cutsem,

The Lancet Oncology

2014

2.4K

Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial

Kohei Shitara, Mustafa Özgüroğlu, Yung‐Jue Bang,

The Lancet

2018

1.3K

Randomized, Open-Label, Phase III Study Comparing Irinotecan With Paclitaxel in Patients With Advanced Gastric Cancer Without Severe Peritoneal Metastasis After Failure of Prior Combination Chemotherapy Using Fluoropyrimidine Plus Platinum: WJOG 4007 Trial

Shuichi Hironaka, Shinya Ueda, Hirofumi Yasui,

Journal of Clinical Oncology

2013

548

Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naïve patients with advanced gastric cancer

Yasuhide Yamada, Katsuhiko Higuchi, Kazuhiro Nishikawa,

Annals of Oncology

2014

524

Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial

Toshihiro Kudo, Yasuo Hamamoto, Ken Kato,

The Lancet Oncology

2017

378

Long-Term Toxicity After Definitive Chemoradiotherapy for Squamous Cell Carcinoma of the Thoracic Esophagus

Satoshi Ishikura, Keiji Nihei, Atsushi Ohtsu,

Journal of Clinical Oncology

2003

368

Three-arm Phase III Trial Comparing Cisplatin Plus 5-FU (CF) Versus Docetaxel, Cisplatin Plus 5-FU (DCF) Versus Radiotherapy with CF (CF-RT) as Preoperative Therapy for Locally Advanced Esophageal Cancer (JCOG1109, NExT Study)

Kenichi Nakamura, Ken Kato, Hiroyasu Igaki,

Japanese Journal of Clinical Oncology

2013

296

Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial

Charles S. Fuchs, Kohei Shitara, Maria Di Bartolomeo,

The Lancet Oncology

2019

276

Association of multiple Lugol-voiding lesions with synchronous and metachronous esophageal squamous cell carcinoma in patients with head and neck cancer

Manabu Muto, Shuichi Hironaka, Mari Nakane,

Gastrointestinal Endoscopy

2002

238

Nab-paclitaxel versus solvent-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE): an open-label, randomised, non-inferiority, phase 3 trial

Kohei Shitara, Atsuo Takashima, Kazumasa Fujitani,

˜The œLancet. Gastroenterology & hepatology

2017

215

Page 1